Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.09 SEK | -3.44% | -1.59% | -21.67% |
25/04 | Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
27/03 | Enzymatica AB Announces Composition of Nomination Committee | CI |
Sales 2024 * | 6M 64.03M 500M | Sales 2025 * | 11.54M 123M 963M | Capitalization | 51.93M 555M 4.33B |
---|---|---|---|---|---|
Net income 2024 * | -4M -42.72M -334M | Net income 2025 * | -1M -10.68M -83.46M | EV / Sales 2024 * | 9.07 x |
Net Debt 2024 * | 2.46M 26.28M 205M | Net cash position 2025 * | 1.65M 17.59M 137M | EV / Sales 2025 * | 4.36 x |
P/E ratio 2024 * |
-12.5
x | P/E ratio 2025 * |
-21.4
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.33% |
1 day | -3.44% | ||
1 week | -1.59% | ||
Current month | +1.98% | ||
1 month | -12.96% | ||
3 months | +1.48% | ||
6 months | -9.12% | ||
Current year | -21.67% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Thomas Blom
FOU | Founder | 59 | 01/07/01 |
Claus Egstrand
CEO | Chief Executive Officer | 63 | 18/17/18 |
Director of Finance/CFO | 55 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bengt Baron
CHM | Chairman | 62 | 19/16/19 |
Director/Board Member | 56 | 15/16/15 | |
Director/Board Member | 57 | 01/21/01 |
Date | Price | Change | Volume |
---|---|---|---|
16/24/16 | 3.09 | -3.44% | 2 128 |
15/24/15 | 3.2 | -1.54% | 63,370 |
14/24/14 | 3.25 | +3.17% | 95,036 |
13/24/13 | 3.15 | +0.32% | 49,176 |
10/24/10 | 3.14 | +0.64% | 83,579 |
Delayed Quote Nasdaq Stockholm, May 16, 2024 at 04:16 pm IST
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.67% | 51.93M | |
+35.01% | 709B | |
+30.41% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.45% | 239B | |
+9.51% | 211B | |
-4.17% | 203B | |
+10.77% | 171B |
- Stock Market
- Equities
- ENZY Stock